--- title: "Healthcare & Clinical Research Diversity: Challenges & Opportunities" description: Healthcare has a longstanding history of underrepresentation of communities of color. It often begins with the clinical trial process, where longstanding a image: https://blog.acclinate.com/hubfs/Imported_Blog_Media/65b7a501a3c9e67c0e175082_Diversity-in-Healthcare-%26-Clinical-Research--Challenges-%26-Opportunities-.jpg --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Diversity in Clinical Trials](https://blog.acclinate.com/topic/diversity-in-clinical-trials) [Health Equity](https://blog.acclinate.com/topic/health-equity) # Diversity in Healthcare & Clinical Research: Challenges & Opportunities Healthcare has a longstanding history of underrepresentation of communities of color. It often begins with the clinical trial process, where longstanding a ![Diversity in Healthcare & Clinical Research: Challenges & Opportunities](https://blog.acclinate.com/hubfs/Imported_Blog_Media/65b7a501a3c9e67c0e175082_Diversity-in-Healthcare-%26-Clinical-Research--Challenges-%26-Opportunities-.jpg) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Acclinate](https://blog.acclinate.com/hubfs/69b96486c4b036c19f462c19_acclinate-logo.png) [Acclinate](https://blog.acclinate.com/author/acclinate) Acclinate turns trust and data into better representation. Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/diversity-in-healthcare-clinical-research-challenges-opportunities) [**](https://twitter.com/home?status=https://blog.acclinate.com/diversity-in-healthcare-clinical-research-challenges-opportunities) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/diversity-in-healthcare-clinical-research-challenges-opportunities&title=Healthcare%20&%20Clinical%20Research%20Diversity:%20Challenges%20&%20Opportunities) Stay up to date Get news directly in your inbox Healthcare has a longstanding history of underrepresentation of communities of color. It often begins with the clinical trial process, where [longstanding and well-established mistrust](https://www.commonwealthfund.org/publications/newsletter-article/2021/jan/medical-mistrust-among-black-americans) of the industry makes it difficult to recruit Black participants. The impact of the lack of diversity in healthcare and medical research further extends to limited treatment options and poor clinical outcomes for communities of color. Though efforts to address the issue are long overdue, momentum is building — especially in the field of clinical research, where underrepresentation can critically impact the efficacy of treatment protocols and pharmaceutical development. FDA draft guidance released in 2022 is pushing life science organizations to increase diversity in clinical trials, even before drug therapies and medical devices are close to market. That said, medical research companies cannot underestimate the importance of building trust within communities of color as they rethink how they engage and recruit with populations that have been left on the sidelines. [![Download Now – Increasing Diversity in Clinical Trials: A Comprehensive Guide for Pharma Companies](https://no-cache.hubspot.com/cta/default/19943632/interactive-169988622868.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKIKXQWGBnQ%2FL858PgLUP54IzOgP3E7qDfSTfu%2F8Dgig3ZHfOqGQgdSZR4J5B52D7PP04LZmMM1A86e7PtIJoScNW5LGF0Wkhmmywgldlqspyab7bMtQhzHb1cf9rT6iLHgdNMsijq71qtApVjlCqo2WfWGNeadE9cwBfsDF6%2Fpoyd%2FAEk1GS6BBgGFgDHMAkLw%2BXUTSrRhnv8FR2cFVmSYc4TyO%2FFscyilRQ%3D%3D&webInteractiveContentId=169988622868&portalId=19943632) ## **A History of Exploitation and a Legacy of Mistrust** Examples of unethical treatment of communities of color by medical professionals in the United States aren’t hard to come by.   J. Marion Sims, often considered the father of gynecology, conducted research on enslaved Black women without anesthesia – and arguably without consent – in developing treatments for vesicovaginal fistula in the mid-19th century. Though some argue the women would have otherwise gone untreated, others suggest they [endured needless suffering](https://www.history.com/news/the-father-of-modern-gynecology-performed-shocking-experiments-on-slaves). Sims himself admitted one patient’s “agony was extreme.” The [infamous Tuskegee experiment](https://www.history.com/news/the-infamous-40-year-tuskegee-study) withheld syphilis treatment from  hundreds of Black men for decades in an effort to understand the disease’s long-term progression – even after penicillin was identified as a successful remedy. The experiment ended only after a reporter broke the story in 1972, 40 years after the study began. A subsequent federal investigation concluded, in the words of Tuskegee University, that “scientific research protocol routinely applied to human subjects was either ignored or deeply flawed.” In 1951, Henrietta Lacks sought treatment for cervical cancer at Johns Hopkins. Without her consent, researchers sampled cells from her cervix. After learning the cells could grow in a lab setting, researchers shared Lacks’ cells. They have since been used to develop treatments for infertility, polio, and COVID-19 – but it wasn’t until August 2023 that [Lacks’ family received compensation](https://newrepublic.com/post/174758/biotech-firm-paying-big-time-henrietta-lacks-family-settlement) from the companies that benefited from her cells. This legacy of unethical behavior and exploitation has caused mistrust. Surveys have shown that Black patients are twice as likely as white patients to believe they will [undergo treatment without their consent](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241476/), as well as one-and-a-half times as likely to believe they would be prescribed experimental medications without their knowledge.   Not surprisingly, this mistrust makes it difficult to recruit individuals from communities of color for clinical trials – which, by their nature, are experimental procedures. ## **Clinical Trial Representation: Where Do We Stand Now?** The [U.S. Food and Drug Administration (FDA)](https://www.fda.gov/media/145718/download) reports that in 2020, only 11% of participants in new drug trials were Hispanic, and only 8% of participants were Black. These communities of color comprise 19% and 14% of the U.S. population, respectively. Meanwhile, a [2022 *Lancet* literature review ](https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00069-2/fulltext)found 25% of clinical trials had no Hispanic enrollees, and 21% had no Black enrollees. Underrepresentation in clinical trials has a significant downstream impact on health disparities, as practitioners have limited data about which treatment options work best in non-white patients. In fact, the Centers for Disease Control and Prevention (CDC) reported patients from communities of color have a higher prevalence of obesity and diabetes than white Americans. There’s an economic cost as well. The diagnosis of a chronic condition makes it difficult for someone to work, decreases their life expectancy, and increases healthcare spending. Research from the University of Southern California suggested that if increasing clinical trial diversity led to just a 1% improvement in disparities, economic gains on the order of $40 billion for diabetes and $60 billion could be realized. That’s a substantial dent in the nation’s ever-rising healthcare spending – and a significant impact on the quality of life in communities of color feeling the effects of unethical medicine and systemic racism. ## **The Health Equity and Accountability Act: Overdue Efforts Gain Momentum** Since 2003, members of the Congressional Tri-Caucus have periodically introduced the Health Equity and Accountability Act. Most recently [re-released in 2022,](https://robinkelly.house.gov/media-center/press-releases/rep-robin-kelly-introduces-health-equity-and-accountability-act) the [bill strives to evaluate health disparities](https://www.booker.senate.gov/news/press/booker-warnock-introduce-legislation-to-advance-health-equity),  strengthen health data collection and healthcare research, improve diversity in healthcare’s workforce, address systemic barriers to accessing care, and assess environmental factors that influence health. To date, more than 300 health equity organizations have helped shape the bill. No action was taken on the bill, and its history of [introduction and referral to committee](https://www.congress.gov/bill/108th-congress/house-bill/3459) means it may be some time before the Health Equity and Accountability Act officially becomes law. However, other recent activity on Capitol Hill shows elected officials and federal agencies are beginning to get serious about how to improve diversity, equity, and inclusion in healthcare and life sciences.   The aforementioned FDA draft guidance on improving diversity in clinical trial enrollment is an important step forward. Additionally, the [Food and Drug Omnibus Reform Act of 2022 (FDORA)](https://www.thefdalawblog.com/wp-content/uploads/2023/01/HPM-FDORA-Summary-and-Analysis.pdf) specifically requires a “diversity action plan” for certain late-stage trials for drugs and devices. FDORA also pushes the FDA to issue guidance for conducting decentralized clinical trials, which is a valuable practice for increasing enrollment and ongoing participation among communities of color and other underrepresented populations.   ## **How to Improve Diversity, Equity, and Inclusion in Clinical Trials** There are clear regulatory, business, and ethical reasons for the industry to [improve representation in clinical trials](https://www.acclinate.com/for-pharmaceutical-companies). However, it’s not enough to identify communities of color for possible enrollment. It’s imperative to *connect* with these communities – to build trust where it hasn’t existed before, provide resources respectful of and tailored to communities of color, and advocate for measurable and meaningful change with active engagement. Only then will diversity in healthcare and life sciences become effective for your business — and start to become standard practice.   Boost inclusivity in trials faster and for the long term by zeroing in on the populations you lack. Acclinate gives you access and authentic connection to communities of color through NOWINCLUDED, a trusted health education and engagement source created by and for the Black/African American community. We then facilitate engagement around your trials, analyzing the data generated to predict and plan where and when your next effort should happen to create the ongoing representation you need. To learn more, [schedule a 1:1 meeting](https://www.acclinate.com/request-a-demo). [![Increasing Diversity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/interactive-170609956904.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLhlj5%2BB4TeN5mqyzxPNZZ8%2F16S4amhaWHgWgippaVWhkB6DGEDrT%2BFebtORL%2Bqt%2BqqnZZHX%2B4giZ4F%2FRsRvKW8yJORq%2FLYbVm5EdZvCe8BQxqKbwet9DDUX4MlsxyIhkKY%2FuB0JtOZy5Afi3PC2bojDuWygvvtSEnkHGOv5HqwIBRjjdPmZe3a4UZq5uh4Urc1szO7Q4A%2Bujg62rJCDkvHBqG82Ab7kQ4JpA%3D%3D&webInteractiveContentId=170609956904&portalId=19943632) ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Acclinate", "url" : "https://blog.acclinate.com/author/acclinate" }, "dateModified" : "2026-06-18T19:24:51.277Z", "datePublished" : "2024-01-29T17:48:00.000Z", "headline" : "Healthcare & Clinical Research Diversity: Challenges & Opportunities", "image" : [ "https://blog.acclinate.com/hubfs/Imported_Blog_Media/65b7a501a3c9e67c0e175082_Diversity-in-Healthcare-&-Clinical-Research--Challenges-&-Opportunities-.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/diversity-in-healthcare-clinical-research-challenges-opportunities", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```